Teva Pharmaceutical Industries (TEVA) and Samsung Bioepis said Friday that they have signed an agreement to develop and commercialize Epysqli, Samsung Bioepis' biosimilar to Alexion Pharmaceuticals' Soliris, in the US.
Under the terms of the deal, Samsung Bioepis will oversee the development, regulatory registration, manufacture, and supply of Epysqli, while Teva will be responsible for its commercialization in the US.
Financial terms were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.